Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Masimo reported strong financial results for the first quarter of 2024 with consolidated revenue at $492.8 million, including healthcare revenue of $339.6 million and non-healthcare revenue of $153.2 million. GAAP net income per diluted share was $0.35 and Non-GAAP net income per diluted share was $0.77. The company saw improvements in gross margins in healthcare and is increasing guidance for healthcare revenues and EPS for 2024. Masimo also announced plans to separate its consumer business.
Masimo, a global leader in monitoring technologies, received FDA clearance for Stork™, an over-the-counter baby monitoring system for infants up to 18 months. The system provides continuous monitoring of oxygen saturation, pulse rate, and skin temperature without a prescription. It offers visual and audible alarms if readings fall outside preset ranges, utilizing advanced pulse oximetry technology. Stork is available at major retailers and online, with additional alarm features through a mobile app update. Stork features a sleek design, patented SET® sensor technology, and a camera with future AI-based features. It is FDA-cleared for OTC use, suitable for infants and neonates in home environments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.